Intravitreal bevacizumab for retinal vein occlusion and early growth of epiretinal membrane: A possible secondary effect?

Joaquin Marticorena, Mario R. Romano, Heinrich Heimann, Theodore Stappler, Kurshid Gibran, Carl Groenewald, Ian Pearce, David Wong

Research output: Contribution to journalArticle

Abstract

Aims: To report the early development of epiretinal membranes (ERM) in eyes with retinal vein occlusions (RVO) treated with intravitreal bevacizumab and to describe possible mechanisms that may be involved in the growth and contraction of these lesions. Methods: Retrospective and interventional study that included 25 eyes of 25 patients with RVO (16 eyes with central retinal vein occlusion and nine eyes with branch retinal vein occlusion). After an initial 2.5 mg/0.1 ml intravitreal bevacizumab injection all patients were followed-up every 6 weeks. Re-treatments were based on visual acuity and optical coherence tomography findings. Results: Twenty-five eyes were treated with bevacizumab and followed for 8.3 (range 4.5-13.5) months. Four eyes developed an ERM within 6-7 weeks after the administration of bevacizumab. ERM was not associated with further deterioration of visual acuity or metamorphopsia in these patients. A rebound of macular oedema was observed in one patient with ERM and in two other patients. No other side effects were observed. Conclusions: Intravitreal bevacizumab may be associated with an early growth of ERM in eyes with RVO, although a causative relationship cannot be established. Future randomised clinical trials are necessary to determine the efficacy and safety profile of this novel therapy.

Original languageEnglish
Pages (from-to)391-395
Number of pages5
JournalBritish Journal of Ophthalmology
Volume95
Issue number3
DOIs
Publication statusPublished - Mar 2011

ASJC Scopus subject areas

  • Ophthalmology
  • Sensory Systems
  • Cellular and Molecular Neuroscience

Fingerprint Dive into the research topics of 'Intravitreal bevacizumab for retinal vein occlusion and early growth of epiretinal membrane: A possible secondary effect?'. Together they form a unique fingerprint.

  • Cite this

    Marticorena, J., Romano, M. R., Heimann, H., Stappler, T., Gibran, K., Groenewald, C., Pearce, I., & Wong, D. (2011). Intravitreal bevacizumab for retinal vein occlusion and early growth of epiretinal membrane: A possible secondary effect? British Journal of Ophthalmology, 95(3), 391-395. https://doi.org/10.1136/bjo.2009.177287